Mitochondrial DNA variation and cancer

Variation in the mitochondrial DNA (mtDNA) sequence is common in certain tumours. Two classes of cancer mtDNA variants can be identified: de novo mutations that act as 'inducers' of carcinogenesis and functional variants that act as 'adaptors', permitting cancer cells to thrive in different environments. These mtDNA variants have three origins: inherited variants, which run in families, somatic mutations arising within each cell or individual, and variants that are also associated with ancient mtDNA lineages (haplogroups) and are thought to permit adaptation to changing tissue or geographic environments. In addition to mtDNA sequence variation, mtDNA copy number and perhaps transfer of mtDNA sequences into the nucleus can contribute to certain cancers. Strong functional relevance of mtDNA variation has been demonstrated in oncocytoma and prostate cancer, while mtDNA variation has been reported in multiple other cancer types. Alterations in nuclear DNA-encoded mitochondrial genes have confirmed the importance of mitochondrial metabolism in cancer, affecting mitochondrial reactive oxygen species production, redox state and mitochondrial intermediates that act as substrates for chromatin-modifying enzymes. Hence, subtle changes in the mitochondrial genotype can have profound effects on the nucleus, as well as carcinogenesis and cancer progression. Variation in mitochondrial DNA (mtDNA) is common in certain tumours. This Review discusses the relevance of heritable, somatic and ancient mtDNA variants to cancer and how subtle changes in mtDNA result in metabolic, epigenetic and transcriptional changes that affect carcinogenesis.

Automated summary

Variation in mitochondrial DNA is common in certain tumors. This review discusses the relevance of heritable, somatic, and ancient mtDNA variants to cancer, and how subtle changes in mtDNA lead to metabolic, epigenetic, and transcriptional changes that affect carcinogenesis.